Kevin Cotter [Call Starts Abruptly] will follow the formal presentation. If you have questions during the presentation, you can type them into the chat to be answered during the question-and-answer period. Questions can only be seen by the moderator. As a reminder, this conference call is being recorded. Before we begin the formal presentation, I’d like to remind everyone that statements made on this call and webcast may contain provisions, estimates and other information that might be considered forward-lo ...

Financial Data and Key Metrics Changes - The company is unable to provide detailed financial results due to the deconsolidation of Invizyne's financial statements, which has delayed the filing of the 10-K report [6][14][25] - As of December 31, the combination of cash and securities was $28 million, with Big Idea investments represented by eXoZymes valued at $64 million, totaling approximately $93 million in cash and securities [58] - The stock price as of December 31 was $6.30, with approximately 9.9 million shares outstanding, resulting in a market value of $62 million, indicating a negative market value of $30 million [58][59] Business Line Data and Key Metrics Changes - The company has successfully launched eXoZymes, marking a significant achievement despite challenging market conditions for small IPOs [14][15] - The shareholder count has increased by 12%, reaching approximately 1,800 shareholders [15] - The onboarding of investors through MDB Direct has begun, with over 500 accounts established by year-end [16] Market Data and Key Metrics Changes - There is a growing demand for microcap financing, with investors seeking liquid alternatives, positioning the company as a top curator of public venture opportunities [32] - The traditional venture capital and private equity markets are facing challenges, leading to increased interest from companies looking to go public [30][31] Company Strategy and Development Direction - The primary strategic priority for the company is to expand its investor community, focusing on partnerships with RIAs and angel groups [35][41] - The company aims to present one to two new Big Idea investment opportunities in the next quarter, indicating a robust pipeline of potential investments [52][53] - The company is evolving from a model of episodic deal-making to creating a consistent public venture asset class portfolio [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the increasing number of opportunities being presented, both from community members and through proactive curation [26][27] - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] - The company is focused on maintaining operational efficiencies while managing cash expenditures, with hopes of reducing operational costs over the next 12 months [62] Other Important Information - The company has licensed new assets from Mayo Clinic and is developing this opportunity, although no specific updates were provided [49][50] - The company continues to work with HeartBeam, which is developing groundbreaking technology for self-administered ECGs, with significant market potential [44] Q&A Session Summary Question: Does Lou Basenese still work for the organization? - Lou Basenese has left the company but remains a friend and supporter, focusing on his media presence [65][66] Question: What does the deconsolidation mean for MDB stockholders and eXoZymes' investors? - The deconsolidation will clarify the financials of MDB, separating its performance from eXoZymes, making it easier for investors to understand [70][71] Question: How many Big Idea companies are expected to be established in 2025? - The company anticipates presenting three to four new Big Ideas in 2025, with some companies already in advanced discussions for potential IPOs [80][81] Question: How do you see the regulatory winds changing? - The regulatory environment is expected to improve, facilitating new offerings, although there are uncertainties regarding FDA timelines [87][88] Question: When do you expect to make any type of dividend? - The company aims to wait for a solid footing under eXoZymes before considering any distributions to avoid disrupting the market [92][93] Question: How should shareholders think about the investment in cash and resources relative to value creation? - The company intends to maintain a modest amount of cash for new opportunities while leveraging existing investments to create value [99][100]

Core Insights - The PatentVest Pulse report highlights the significance of intellectual property (IP) control in shaping the future of brain-computer interfaces (BCIs) and neurotechnology [1][4] - Neurological disorders are a rapidly growing area in global healthcare, with BCIs emerging as a next-generation solution to address these challenges [2][3] Market Overview - The U.S. BCI market is projected to exceed $400 billion, with $80 billion focused on high-acuity patient populations and $320 billion in long-term potential across broader neurological and psychiatric conditions [3] - Early alignment of IP, clinical validation, and commercialization strategies will be crucial for companies to scale in this vast market [3] Competitive Landscape - The report provides a comprehensive analysis of the BCI market, profiling key players such as Synchron, Neuralink, Blackrock Neurotech, and others, while mapping over 2,160 patent families across 664 entities [4][9] - Companies like Synchron and INBRAIN are establishing leadership through innovative strategies, while Neuralink garners significant media attention [6][9] Intellectual Property Dynamics - More than 2,160 unique BCI patent families are held by various companies, indicating an accelerating competition for control over system-level IP [9] - Academic institutions, including Tianjin University and Stanford, continue to dominate early-stage innovation, holding foundational patents that support commercial efforts in the BCI space [9]

Investment Strategy - MDB Capital Holdings operates as a foundational platform for financing startups, focusing on community-driven micro and small-cap financings ranging from $5 million to $60 million[23]. - MDB's investment strategy includes a two-step financing approach, providing initial seed capital of $5 million to $10 million, followed by additional funding of $20 million to $60 million for commercialization[31]. - MDB aims to take a majority ownership stake in partner companies, planning to seek one or two partner company opportunities per year[54]. - MDB intends to maintain at least 35% voting stock in partner companies, ensuring influence over management and strategic direction[55]. - MDB's investment philosophy focuses on identifying early-stage companies with disruptive technologies that can sustain value in public markets[29]. Partner Companies and Development - The Big Idea Pipeline identifies approximately 250 technologies annually, narrowing down to about 50 active Big Idea Companies, with two currently in active negotiations for potential partnership or investment[26]. - MDB's partner companies must demonstrate "Tech Leadership Potential," "Platform Technology," and "Large Market Potential," ensuring a robust intellectual property position[27]. - Three companies founded by MDB, Provention Bio, Cue BioPharma, and Pulse Biosciences, have traded at or above $1 billion in market value, enhancing their ability to raise capital for commercialization[34]. - MDB's model emphasizes long-term involvement with partner companies, including board membership and strategic business advice post-IPO[32]. - The company aims to create a strong foundation for partner companies during their development phase to attract top talent and ensure long-term success[39]. Community and Investor Relations - MDB's community consists of over 500 sophisticated investors who support the public venture model and advocate for the partner companies[45]. - MDB shareholders can buy or sell shares in the holding company at any time, participating in capital formation through private placements or public offerings[52]. - The company expects to provide substantial capital to partner companies more easily than traditional venture capital, enhancing growth potential[51]. - MDB's public venture model is designed to offer liquidity, efficiency, and transparency, addressing the unique needs of early-stage companies[49]. Intellectual Property and Technology Commercialization - PatentVest is expanding operations to optimize technology commercialization, transforming complex legal processes into manageable business processes[75]. - The company plans to leverage its proprietary patent database to enhance the value of inventions and guide strategic business decisions[76]. - PatentVest has built a proprietary patent database containing over 148 million patents across 116 countries, enhancing its ability to support technology companies[86]. - The PatentVest process is expected to guide technology companies in prioritizing ideas and developing intellectual property strategies, enhancing their market position[85]. - PatentVest's legal services will focus on intellectual property matters, enhancing the value of inventions through strategic legal support[88]. Regulatory and Compliance Risks - The company’s broker-dealer, Public Ventures, must comply with SEC Regulation S-P, which mandates policies for protecting client information and providing privacy notices[112]. - The company faces risks from potential security breaches, which could lead to significant legal and financial exposure, as well as reputational damage[114]. - The company is subject to stringent privacy and data protection laws, including the Gramm-Leach-Bliley Act and the California Consumer Privacy Act, which could result in liabilities and require modifications to data handling practices[183][184]. - The California Privacy Rights Act, effective January 1, 2023, imposes additional obligations on the company regarding data privacy and may increase compliance costs[184]. - The company anticipates that more states will enact privacy legislation similar to the CCPA, which could complicate compliance and increase legal risks[186]. Operational Structure and Growth - The company currently employs approximately 16 full-time employees and engages consultants for various activities, indicating a lean operational structure[127]. - The company anticipates growth in the number of employees and consultants as operations expand[129]. - The company has funded operations primarily through equity financings and revenue generated by services since inception in 2022[143]. - The company may require additional capital to support operations and business growth, which might not be available when needed[143]. - The business model does not rely on operating cash flows from partner companies, which are expected to not generate revenues or positive cash flow during development[147]. Market and Competitive Landscape - MDB faces competition from other capital providers in acquiring and developing partner companies, which may lead to higher acquisition costs and increased risk of loss[177]. - The company recognizes competition from traditional venture capital firms and aims to differentiate through community support and development of partner companies[60]. - Political and regulatory environments in the U.S. and Nicaragua pose risks that could adversely affect MDB's operations and financial condition[164]. - The company believes that the conflicts involving Ukraine and Israel do not have a direct impact on its operations or financial condition, but may have general effects due to international sanctions and inflation[182]. Challenges and Risks for Partner Companies - The company’s partner companies may encounter challenges typical of early-stage companies, including regulatory and market penetration issues[148]. - The company’s management will need to effectively manage growth and expansion of partner companies, which imposes significant responsibilities[149]. - Partner companies may face challenges in protecting their proprietary rights and could infringe on the rights of others, leading to potential litigation[200]. - Limited foreign intellectual property rights may hinder the ability to protect intellectual property globally, impacting competitive position[204]. - Collaborations with third parties are essential for research and development, and failure to maintain these arrangements could adversely affect business[212]. M1 Company Specifics - M1, a partner company, aims to develop a small molecule anti-senescence platform targeting age-related diseases, with the global market projected to reach nearly $45 billion by 2030[91]. - M1 entered into a License Agreement with Mayo, granting exclusive rights to develop and commercialize patented technology, issuing 1,980,000 shares representing 33% of its shares and paying an initial license fee of $150,000[92][93]. - M1 is currently in the pre-clinical development stage, conducting feasibility studies and collecting drug safety data, with milestone payments required for clinical trial initiations[95][96]. - M1's compounds are novel, necessitating extensive safety and efficacy testing to gain market acceptance and regulatory approval[220]. - The success of M1 is highly dependent on hiring and retaining specialized scientific staff, which may be challenging due to high demand for such talent[221].

Core Insights - MDB Capital Holdings, LLC is focused on launching deep technology companies and has made significant progress in a challenging venture market, highlighting the value of its public venture approach [2][6] Operational Highlights - The company successfully completed its first full year of its clearing and trading platform and has expanded its investor community by 12%, onboarding 456 new brokerage accounts and increasing assets under management from approximately $2 million to $44 million [6] - MDB Capital launched an initial public offering for eXoZymes Inc, a company spun out from UCLA, and currently owns about 47% of its outstanding shares [6] - The firm increased its analyst team to 14, screening 8,964 companies and examining 217 for potential market leadership, resulting in a strong pipeline of "Big Ideas" [6] - MDB Capital operates a self-clearing broker-dealer and an online investment platform specifically for public venture investing, enhancing its service offerings [6][8] Financial Reporting - The company filed its Form 10-K with the SEC, which includes consolidated financial results for all operations, including eXoZymes' performance until its IPO on November 14, 2024 [6]

Core Viewpoint - MDB Capital Holdings, LLC plans to host a Zoom webinar on March 31, 2025, to discuss its fourth quarter and full year 2024 results, with a press release to be issued prior to the call [1][2]. Company Overview - MDB Capital Holdings, LLC, founded in 1997, focuses on transforming deep technology ideas into valuable public companies through a unique public venture capital approach, primarily targeting pre-revenue, early-stage companies [3]. - The company operates under the MDB Capital brand, which includes a self-clearing broker-dealer and the PatentVest firm, specializing in intellectual property intelligence and consulting [4].

Core Insights - PatentVest released the "AI-Driven Data Centers – The Patent Race Reshaping AI Infrastructure" report, analyzing the evolving AI data center market and its implications for future infrastructure [1] - The enterprise data generation is expected to reach 1.2 million exabytes by 2025, necessitating advancements in digital infrastructure to support AI workloads [2] - The data center as a service market, valued at $71.92 billion in 2022, is projected to grow to $431.43 billion by 2030, driven by demand for AI-optimized infrastructure [3] Market Dynamics - AI-driven data centers are integrating AI-specific semiconductors, high-speed interconnects, liquid cooling, and renewable energy solutions to enhance efficiency and sustainability [3] - Intellectual property (IP) is crucial for unlocking the potential of evolving data centers, with companies expanding patent portfolios to secure foundational technologies [6] - The report highlights the competitive patent landscape, identifying key players and gaps in patent coverage that present opportunities for innovation [6] Competitive Landscape - The AI data center market is witnessing a surge in patent filings, with 77% of all filings originating from China, indicating its dominant role in shaping AI infrastructure [8] - Leading innovators include five top patent holders from China, one from South Korea, and others from the United States, showcasing a diverse competitive environment [8] - Patent disputes, such as Intel's $2.18 billion ruling and Netlist's $118 million lawsuit against Samsung, emphasize the strategic importance of IP in the sector [8]

Core Insights - The continuous glucose monitoring (CGM) market is rapidly evolving, driven by technological advancements and increasing demand for diabetes management solutions [1][3][5] Market Overview - The CGM market was valued at $11.63 billion in 2024 and is projected to reach $21 billion by 2029, indicating significant growth potential [3] - An estimated 537 million adults were affected by diabetes in 2021, with projections rising to 783 million by 2045, highlighting the urgent need for effective diabetes management tools [2] Key Players and Innovations - Major companies such as Dexcom, Abbott, Medtronic, and Roche are leading the way in advancing CGM technologies and solutions [5] - Innovations include non-invasive glucose monitoring and integration with mobile applications, enhancing convenience and accuracy for users [8] Market Dynamics - The emergence of over-the-counter (OTC) CGM products is expanding access to diabetes care, particularly for non-insulin-dependent patients and wellness-focused individuals [8] - A surge in patent filings indicates a competitive landscape where companies are actively protecting their innovations [8] Intellectual Property Strategy - The CGM market is characterized by ongoing litigation trends, reflecting the high stakes involved in securing leadership positions through intellectual property [8]

Core Insights - Invizyne Technologies, Inc. has been awarded a $2 million project to enable enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF) [1][2] - The project is part of the U.S. Department of Defense's BioMADE initiative, aimed at scaling up American biomanufactured products [2][3] - The global SAF market is projected to grow at a compound annual growth rate of 52.2%, reaching $27.4 billion by 2032 [5] Project Details - The BioMADE grant will facilitate the development of an enzyme production and processing pipeline for isobutanol, which can replace conventional petroleum-based fuels [6][4] - Invizyne's technology will be deployed in 100L pilot-scale facilities as part of this initiative [6] Broader Vision and Impact - Invizyne aims to establish a framework for expanding its cell-free approach into various industrial processes beyond biofuels [8] - The company believes its biomanufacturing platform, SimplePath™, will provide significant alternatives to traditional chemical production methods [11][10] - The initiative is expected to contribute to reducing greenhouse gas emissions and fostering a shift toward renewable solutions [8][7] Industry Context - BioMADE supports the scale-up of bioindustrial manufacturing technology, enhancing American competitiveness and securing the U.S. supply chain [9] - The initiative is part of a broader effort to build a diverse and competitive workforce in the bioindustrial manufacturing ecosystem [9]

Company Overview - Invizyne Technologies, Inc. specializes in cell-free, enzyme-based biomanufacturing systems aimed at producing commercially important molecules and chemicals for everyday life [6] - The company is headquartered in Monrovia, California, and is focused on redefining biomanufacturing through its SimplePath™ platform, which transforms natural or renewable resources into valuable biochemicals [6] Initial Public Offering (IPO) Details - Invizyne Technologies announced the closing of its IPO, offering 1,875,000 shares at a public offering price of $8.00 per share, resulting in gross proceeds of approximately $15,000,000 before expenses [1][2] - The shares began trading on NASDAQ under the ticker symbol "IZTC" on November 13, 2024 [1] - The company has granted a 45-day option to the underwriter to purchase up to 281,250 additional shares to cover over-allotments [2] Concurrent Private Placement - In a concurrent private placement, Invizyne issued 93,750 warrants at a purchase price of $0.125 per warrant, each warrant allowing the purchase of one share of common stock at an exercise price of $8.00 for five years [3] Regulatory Compliance - A registration statement on Form S-1 was filed with the SEC and declared effective on November 8, 2024, allowing the public offering to proceed [4]